Please provide your email address to receive an email when new articles are posted on . SLESIS-R predicts severe infections in lupus more accurately than SLESIS. Its simpler design could make SLESIS-R ...

Skin manifestations are common in patients with SLE. A recent study reported increased site-specific recurrence of cutaneous lupus erythematosus (CLE).1 While this study included a proportion of ...

Patients with systemic lupus erythematosus who receive belimumab monotherapy show comparable remission rates and disease control to those who receive combination therapy with immunosuppressants.

A new study found statin use is associated with reduced disease activity and inflammation in people with systemic lupus ...

As The European Lupus Society’s 15th annual soiree approaches, the Clinical Trials Arena team takes a look at four promising therapies in the SLE pipeline.

Blood dendritic cell antigen 2 (BDCA2) is a receptor that is exclusively expressed on plasmacytoid dendritic cells, which are implicated in the pathogenesis of lupus erythematosus. Whether treatment ...